Cytosorbents (CTSO) Other Accumulated Expenses (2018 - 2026)

Cytosorbents' Other Accumulated Expenses history runs 9 years deep, the most recent figure standing at $268000.0 for Q1 2026.

• Quarterly Other Accumulated Expenses fell 66.37% year-over-year to $268000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $268000.0 (down 66.37% YoY) and the FY2025 annual result came in at $271000.0, down 1.45% from the prior year.
• Other Accumulated Expenses was $268000.0 for Q1 2026 at Cytosorbents, down from $271000.0 in the prior quarter.
• Across five years, Other Accumulated Expenses topped out at $991545.0 in Q4 2023 and bottomed at $268000.0 in Q1 2026.
• A 5-year average of $470483.5 and a median of $284500.0 in 2025 frame the typical range for Other Accumulated Expenses.
• Annual changes were most pronounced in 2023 — Other Accumulated Expenses surged 67.38% — and 2024, when it sank 72.27%.
• Cytosorbents' Other Accumulated Expenses stood at $592398.0 in 2022, then jumped by 67.38% to $991545.0 in 2023, then sank by 72.27% to $275000.0 in 2024, then dropped by 1.45% to $271000.0 in 2025, then dropped by 1.11% to $268000.0 in 2026.
• Business Quant data shows CTSO's Other Accumulated Expenses at $268000.0 in Q1 2026, $271000.0 in Q4 2025, and $282000.0 in Q3 2025.